Health-related quality of life in early @entity309 : XXXX and treatment response.

@entity1 @entity66 @entity625 @entity1499 @entity309
OBJECTIVE: To document the burden of early @entity309 ( @entity309 ) on health-related quality of life (HQL) and compare changes in HQL across 2 treatments. STUDY DESIGN: Analysis of HQL scores among @entity1 enrolled in a multicenter, double-blind, randomized control trial of early @entity309 treatment. @entity1 AND METHODS: A total of 424 @entity1 with early @entity309 were randomized to 1 of 2 treatment groups: etanercept or @entity1499 . @entity1 were treated and followed for 52 weeks. Health-related quality of life was assessed before and throughout treatment using the Medical Outcomes Study Short Form 36 Health Survey (SF-36) and the Health Assessment Questionnaire (HAQ). The HQL burden of @entity309 was established by comparing SF-36 scale scores to general US population norms. The impact of treatment on HQL was determined by comparing scores on both SF-36 and HAQ scales. RESULTS: Before treatment, @entity309 @entity1 showed significant decrements in scores on all SF-36 scales and summary measures in comparison with age- and sex-matched general US population norms, multivariate analysis of variance (MANOVA) F(8,2815) = 204.6, P < .0001. After 52 weeks of treatment, 7 of 8 SF-36 scales and the physical summary measure remained significantly below the general US population norm, MANOVA F(8,2815) = 41.9, P < .0001. @entity1 randomized to etanercept showed significantly better HQL improvement earlier in treatment than @entity1 randomized to @entity1499 on the SF-36 physical summary, MANOVA F(10,4230) = 6.1, P< .0001, the SF-36 @entity625 -specific health index, MANOVA F(10,4230) = 8.5, P < .0001, and the HAQ, MANOVA F(10,4230) = 14.7, P < .0001. At 52 weeks, there were no significant differences between treatment groups. CONCLUSIONS: @entity309 places @entity66 burden on @entity1 ' HQL. Successful treatment of early @entity309 improved HQL. Etanercept showed a rapid HQL response.
